> NexMed (NEXM) is a pharmaceutical and medical technology company that
> focuses on developing and commercializing therapeutic products. This
> excellent drug developer has a significant range of innovative
> pharmaceutical products that solves a host of medical needs. The
> Company's new products are based on an enhancement drug technology
> known as NexACT, which can enable an active drug to function
> effectively.
> * NexAct Technology
> NEXM drug technology - NexACT - represents an important breakthrough
> in providing a highly effective therapeutic approach. The patented
> NexACT technology utilizes highly effective formulations. The NexACT
> system can create new products that not only provide patients with
> added therapeutic benefits, but also extend the product life for an
> additional 20 years under the multiple patent protection of the NexACT
> technology.
> * Commercial Potential
> NEXM produces Vitaros serving over 200 million people worldwide. In
> addition, the current treatment market is estimated at $3 billion
> worldwide and is projected to expand to $5 billion.
> NEXM is also producing more than $150 billion brand-name drug
> products. This represents a significant opportunity for converting
> some of those products for better patient compliance or for added
> therapeutic benefit.
discussions
